# Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study

> **NCT07294547** · NA · RECRUITING · sponsor: **National Taiwan University Hospital** · enrollment: 80 (estimated)

## Conditions studied

- Kidney Transplantation, Cytomegalovirus Infections
- EBV Infection
- Antiviral Prophylaxis

## Interventions

- **DRUG:** Valacyclovir (Valtrex)
- **DRUG:** Valganciclovir (Valcyte)

## Key facts

- **NCT ID:** NCT07294547
- **Lead sponsor:** National Taiwan University Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-27
- **Primary completion:** 2029-12
- **Final completion:** 2030-12
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07294547

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07294547, "Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07294547. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*